Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cyclophosphamide + Fludarabine + Idecabtagene Vicleucel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Idecabtagene Vicleucel||Abecma||Ide-cel|bb2121||Abecma (idecabtagene vicleucel) is a chimeric antigen receptor T cell specific to B cell maturation antigen (BCMA), which could potentially result in decreased volume of BCMA expressing tumor cells (PMID: 32707894, PMID: 33626253). Abecma (idecabtagene vicleucel) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04196491||Phase I||Lenalidomide Cyclophosphamide + Fludarabine + Idecabtagene Vicleucel||A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) (KarMMa-4)||Active, not recruiting||USA||0|